Analysts Anticipate Intellia Therapeutics Inc (NTLA) Will Announce Earnings of -$0.55 Per Share
Brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings per share of ($0.55) for the current quarter, according to Zacks. Five analysts have provided estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.64). Intellia Therapeutics reported earnings per share of ($0.61) during the same quarter last year, which suggests a positive year over year growth rate of 9.8%. The firm is expected to announce its next quarterly earnings results on Wednesday, March 13th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($2.09) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.89). For the next year, analysts expect that the firm will report earnings of ($2.49) per share, with EPS estimates ranging from ($3.35) to ($1.18). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Intellia Therapeutics.
NTLA has been the subject of a number of research analyst reports. BidaskClub upgraded Intellia Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 6th. BTIG Research started coverage on Intellia Therapeutics in a report on Thursday. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer restated a “hold” rating on shares of Intellia Therapeutics in a report on Wednesday, October 31st. Finally, Leerink Swann started coverage on Intellia Therapeutics in a report on Tuesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $31.50.
Shares of NASDAQ NTLA traded up $0.29 during mid-day trading on Wednesday, reaching $13.73. 60,987 shares of the company’s stock were exchanged, compared to its average volume of 523,890. The stock has a market cap of $582.91 million, a PE ratio of -7.30 and a beta of 2.91. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $35.99.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.